Key Points
- Maze Therapeutics CMO Harold Bernstein sold 15,000 shares on May 14 at an average price of $26.22, totaling about $393,300. The sale cut his stake by 50% and was made under a pre-arranged Rule 10b5-1 plan.
- The insider has been selling repeatedly in recent months, including 15,000 shares on April 1, 15,000 on March 20, and 30,000 on March 10, with prior sales at higher prices.
- Maze reported a wider-than-expected loss in its latest earnings, posting EPS of -$0.45 versus expectations for -$0.43, while analysts still hold a generally bullish view with an average rating of “Buy” and an average price target of $66.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CEO Jason Coloma sold 1,938 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $26.00, for a total value of $50,388.00. Following the completion of the sale, the chief executive officer owned 31,001 shares in the company, valued at approximately $806,026. This represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maze Therapeutics Stock Performance
MAZE opened at $24.50 on Tuesday. The stock has a market cap of $1.36 billion, a P/E ratio of -9.68 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The stock's 50 day simple moving average is $33.00 and its 200 day simple moving average is $37.92. Maze Therapeutics, Inc. has a 1-year low of $9.15 and a 1-year high of $53.65.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.63 EPS for the current fiscal year.
Institutional Investors Weigh In On Maze Therapeutics
Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its holdings in shares of Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock worth $130,197,000 after purchasing an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company's stock worth $70,307,000 after purchasing an additional 362,060 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company's stock worth $26,843,000 after purchasing an additional 94,529 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Maze Therapeutics by 9.0% during the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company's stock worth $35,111,000 after purchasing an additional 69,771 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in shares of Maze Therapeutics by 40.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company's stock worth $31,793,000 after purchasing an additional 222,251 shares during the last quarter.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on MAZE shares. Weiss Ratings restated a "sell (d)" rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Mizuho upgraded Maze Therapeutics to a "strong-buy" rating in a report on Wednesday, March 11th. JPMorgan Chase & Co. increased their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a report on Tuesday, March 31st. Wedbush increased their target price on Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a report on Monday, March 16th. Finally, Guggenheim increased their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $66.00.
View Our Latest Stock Analysis on MAZE
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
